Literature DB >> 26215490

Histopathological Effects of Teriparatide in Medication-Related Osteonecrosis of the Jaw: An Animal Study.

Aydin Keskinruzgar1, Zehra Bozdag2, Mutan Hamdi Aras3, Tuncer Demir4, Umit Yolcu5, Sedat Cetiner6.   

Abstract

PURPOSE: Osteonecrosis of the jaw after tooth extraction is a major complication in patients using bisphosphonates (BPs) for bone lesions, such as for the treatment of osteoporosis. The purpose of this study was to investigate the histopathologic effects of teriparatide (a synthetic parathyroid hormone) on rats developing osteonecrosis with BP use.
MATERIALS AND METHODS: Rats (n = 80) that had been injected intraperitoneally with zoledronic acid for 7 weeks were used. Maxillary first molar extractions and bone defects were established in the same region in the eighth week. Teriparatide was administered subcutaneously to prevent osteonecrosis. Animals were sacrificed and histopathologic changes were examined. Osteoblasts, osteoclasts, inflammatory phase of bone healing, and osteonecrotic areas were evaluated.
RESULTS: The osteoclast numbers were larger in the experimental groups (teriparatide administered before and immediately after tooth extraction) than in the control group (administered zoledronic acid). The inflammatory phase of bone healing was more pronounced in the experimental group (teriparatide administered before tooth extraction) than in the control group. There were significant differences in osteoclast numbers and in the inflammatory phase of bone healing between the experimental and control groups (P < .05). The osteoblast numbers and osteonecrotic areas were similar in size between the experimental and control groups. There were no significant differences (P > .05).
CONCLUSIONS: BPs have negative effects on osteoclasts and the inflammatory phase of bone healing, whereas teriparatide was found to be effective in eliminating the negative effects of BPs. Teriparatide had positive effects in preventing osteonecrosis; therefore, teriparatide could be an effective agent for MRONJ.
Copyright © 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26215490     DOI: 10.1016/j.joms.2015.07.005

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  8 in total

1.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

Review 2.  Anabolic agents: what is beyond osteoporosis?

Authors:  Y Liu; A E Levack; E Marty; O Or; B P Samuels; M Redko; J M Lane
Journal:  Osteoporos Int       Date:  2018-04-07       Impact factor: 4.507

3.  The effect of melatonin on prevention of bisphosphonate-related osteonecrosis of the jaw: an animal study in rats.

Authors:  Afshin Yadegari; Atousa Aminzadeh; Sam Seyyedkhamesi; Maedeh Aminian
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2020-08-31

Review 4.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

5.  Effects of pre-extraction intermittent PTH administration on extraction socket healing in bisphosphonate administered ovariectomized rats.

Authors:  Jae-Young Kim; Hyo-Won Jang; Jung-In Kim; In-Ho Cha
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

6.  Evaluating Osteogenic Differentiation of Osteoblastic Precursors Upon Intermittent Administration of PTH/IGFBP7.

Authors:  Han Xia; Yueyang Tian; Yile Lin; Qia Huang; Yuan Xue
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

7.  Predictive Value of Neutrophil-Lymphocyte Ratio as a Marker in Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Retrospective Analysis.

Authors:  Kazuto Kurohara; Kasumi Shimizu; Taku Murata; Gaku Koizumi; Akira Takigawa; Kokoro Nagata; Kenya Okumura; Naoya Arai
Journal:  Diagnostics (Basel)       Date:  2022-07-29

8.  Enhancement of peri-implant bone formation via parathyroid hormone administration in a rat model at risk for medication-related osteonecrosis of the jaw.

Authors:  Ji Young Park; Hyun A Heo; Suhyun Park; Sung Woon Pyo
Journal:  J Periodontal Implant Sci       Date:  2020-03-19       Impact factor: 2.614

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.